Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
Home > Products > Novel inhibitors

Reversan

  Cat. No.:  DC43400   Featured
Chemical Structure
313397-13-6
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
Get Quotation Now
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
Reversan (CBLC4H10) is a potent and nontoxic inhibitor of two major drug efflux transporters: multidrug resistance-associated protein 1 (MRP1) and P-glycoprotein (Pgp). These transporters are key players in multidrug resistance (MDR), a major obstacle in cancer chemotherapy, as they pump chemotherapeutic drugs out of cancer cells, reducing their intracellular concentration and efficacy. By inhibiting MRP1 and Pgp, Reversan can reverse drug resistance and enhance the effectiveness of chemotherapy agents. Its nontoxic profile makes it a promising candidate for overcoming MDR in cancer treatment.
Chemicals PropertiesBiological activity COA & MSDSRelated productsDatasheet
Cas No.: 313397-13-6
Chemical Name: Reversan
Synonyms: Reversan;N-[3-(4-Morpholinyl)propyl]-5,7-diphenylpyrazolo[1,5-a]pyriMidine-3-carboxaMide;CBLC4H10;N-[3-(4-Morpholinyl)propyl]-5,7-diphenyl-pyrazolo[1,5-a]pyrimidine-3-carboxamide;MLS000570931;Reversan, >=98% (HPLC);REGID_for_CID_2298706;HMS2467O12;HMS3431M07;BDBM50030743;STL504717;N-(3-morpholin-4-ylpropyl)-5,7-diphenylpyrazolo[1,5-a]pyrimidine-3-carboxamide;(R)-4CPG |;AC1M59S6;AGN-PC-0KEHU2;CHEMBL1506885;SCHEMBL14039227;Y15 |;N-[3-(4-Morpholinyl)propyl]-5,7-diphenylpyrazolo[1,5-a]pyrimidine-3-carboxamide;;N-[3-(morpholin-4-yl)propyl]-5,7-diphenylpyrazolo[1,5-a]pyrimidine-3-carboxamide;AKOS001714612;CS-0029046;MFCD01528184;G12988;DTXSID80367845;HY-107643;313397-13-6;GLXC-03910;J-018386;MS-27945;N-(3-Morpholinopropyl)-5,7-diphenylpyrazolo[1,5-a]pyrimidine-3-carboxamide;SMR000193355;NCGC00370816-01;AG-219/11789114;DA-77422;DTXCID90318883
SMILES: O1CCN(CC1)CCCN([H])C(C1C=NN2C(C3C=CC=CC=3)=CC(C3C=CC=CC=3)=NC2=1)=O
Formula: C26H27N5O2
M.Wt: 441.524885416031
Purity: >98%
Sotrage: 0°C (short term), -20°C (long term), desiccated
MSDS
TITLE DOWNLOAD
MSDS_27021_DC43400_313397-13-6
COA
LOT NO. DOWNLOAD
Cat. No. Product name Field of application
DC31074 Isopropyl myristate Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868 AZ14133346 AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865 TI17 ​​TI17​​ represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816 Nisoxetine Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641 GENZ-644282 TFA salt Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325 PSMA-617 TFA PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202 Fosaprepitant free acid Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748 O4I4 O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684 ZH8667 ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646 EB-PSMA-617 EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.
X
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Site Map|Privacy PolicyCopyright © 2018-2020 All Rights Reserved. Technical Support:KuuJia